Disclaimer: This investigation is developing and the timeline of voluntary ranitidine recalls is subject to change. We will regularly update this page to reflect the most recent information involving Zantac or ranitidine recalls.
The online pharmacy Valisure alerted the FDA of the presence of a chemical called N-nitrosodimethylamine (NDMA) in ranitidine products in September 2019. This was quickly followed by the Sandoz division of Novartis Pharmaceuticals stopping the distribution of ranitidine, or generic Zantac.
The latest news of a ranitidine recall came in January 2020, when Northwind Pharmaceuticals issued a voluntary recall for ranitidine tablets on the consumer level. Though not all ranitidine medicines have been recalled in the U.S., those taking Zantac or other ranitidine products may want to consider switching to another medication.
Ranitidine Recall Timeline
From the first announcement of NDMA within Zantac to the most recent voluntary recalls, all the statements, press releases, and media reports can be confusing. Consider a simplified timeline of Zantac or ranitidine recalls, which includes all recalled products containing ranitidine.
This timeline details every important date or announcement involving a Zantac or ranitidine recall, from the earliest to most recent:
- 9/23/2019: Sandoz Inc. issues a voluntary recall of 150mg and 300mg ranitidine hydrochloride (HCI) capsules.
- 9/25/2019: Apotex Corp issues a voluntary, nationwide recall of 75mg and 150mg ranitidine tablets.
- 9/28/2019: CVS Pharmacy suspends all Zantac-brand and CVS Health-brand ranitidine product sales.
- 10/18/2019: Sanofi announces a voluntary recall of all over-the-counter Zantac products in the U.S.
- 10/23/2019: Perrigo Company issues voluntary, worldwide recall of ranitidine products.
- 10/23/2019: Dr. Reddy’s confirms voluntary, nationwide recall of all ranitidine products in the U.S., including medications at Kroger, Walgreens, CVS, and other major pharmacies.
- 10/25/2019: Lannett Company issues voluntary, nationwide recall of 15mg/ml of ranitidine syrup/oral solution.
- 10/25/2019: Novitium Pharma issues voluntary, national recall of 150mg and 300mg ranitidine HCI capsules.
- 11/6/2019: Aurobindo Pharma USA issues voluntary, nationwide recall of 150mg ranitidine tablets, 150mg and 300mg ranitidine capsules, and 15 mg/ml ranitidine syrup.
- 11/8/2019: American Health Packaging (AHP) issues voluntary, nationwide recall of 150mg/10ml ranitidine liquid unit dose cups.
- 11/8/2019: Amneal Pharmaceuticals announces voluntary, nationwide recall of 150mg and 300mg ranitidine tablets and 15mg/ml ranitidine syrup.
- 11/15/2019: Golden State Medical Supply (GSMS) issues voluntary, nationwide recall of ranitidine HCI 150mg and 300mg capsules.
- 11/19/2019: Precision Dose issues voluntary, nationwide recall of ranitidine oral solution, USP 150 mg/10 ml.
- 12/17/2019: Glenmark Pharmaceuticals issues a voluntary recall of 150mg and 300mg ranitidine tablets.
- 1/7/2020: Appco Pharma issues voluntary, nationwide recall of 150mg and 300mg ranitidine HCI capsules.
- 1/8/2020: Denton Pharma (Northwind Pharmaceuticals) voluntarily recalls 150mg and 300mg ranitidine tablets and ceases distribution.
For more information on the particular batch or NDC number of the product label that is being recalled, please visit the FDA’s Recalls, Market Withdrawals, and Safety Alerts webpage.
Our Featured Case Results
Understanding Voluntary Zantac (Ranitidine) Recalls
A voluntary recall makes it sounds like the FDA is giving pharmaceutical companies the choice to recall their product. However, the word voluntary can be misleading.
A voluntary recall means the FDA has discovered something dangerous in the medication and meets with the company to negotiate what steps will be taken to ensure product safety. The goal is to then decide which batches of the medication will be recalled or removed from the market.
A voluntary recall helps salvage the pharmaceutical company’s reputation since the official record will be that they voluntarily recalled the medication. Although the FDA gives pharmaceutical companies the chance to do the right thing, a voluntary recall does not diminish the seriousness of a Zantac or ranitidine recall.
Is A Pharmaceutical Company Liable After A Voluntary Ranitidine Recall?
Although a voluntary recall can limit a company’s liability for damages moving forward, it doesn’t shield the company from failing to make the product safe in the first place.
Several pharmaceutical companies issued voluntary recalls in late 2019 and in early 2020. As we move forward, there are likely to be countless lawsuits against the companies that manufactured or sold ranitidine products.
There are already at least two class action lawsuits that were filed against Sanofi and the former manufacturer of Zantac, Boehringer Ingelheim. The claims state that these companies should have been aware of the cancer-causing risks of patients taking Zantac. However, a class action lawsuit isn’t your only legal option.
We Are Nationally Awarded Lawyers
Contact Florin|Roebig For A Free Zantac Case Evaluation
If you or someone you know has cancer and took Zantac, you may have the right to pursue legal recourse. Although there are pending class-action lawsuits against Zantac manufacturers, your case may be best served by multidistrict litigation (MDL).
To learn more about multidistrict litigation, or to receive a free case evaluation involving a Zantac or ranitidine lawsuit, please contact the offices of Florin|Roebig today.